Global experts, including several from Monash University, have developed guidelines to better manage multiple sclerosis (MS) in people over 50. Subscribe to our newsletter for the latest sci-tech news ...

This perspective introduces MS360°, a conceptual hybrid care model for the management of multiple sclerosis (MS). It integrates traditional on-site assessments with digital health technologies (DHT) ...

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system characterised by inflammatory demyelination, axonal damage and neurodegeneration. Clinical management spans ...

Pavan Bhargava, MD, looks forward to the 2025 Annual Meeting of the American Academy of Neurology, where attendees will learn about the updated diagnostic criteria for relapsing-remitting multiple ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

Improved survival, rather than rising incidence, appears to be the main driver of increasing MS prevalence in France and ...

Researchers conducted a cohort study that suggests oral N-acetylglucosamine treatment can hinder neurodegeneration and inflammation associated with multiple sclerosis (MS). Oral treatment of ...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses ...

Fatigue is experienced by approximately 80% of people with multiple sclerosis, significantly impacting their quality of life and functional ability. To discuss the latest advancements in fatigue ...

Global experts, including several from Monash University, have developed guidelines to better manage multiple sclerosis (MS) in people over 50. First author Associate Professor Anneke van der Walt, ...